Antifungal stewardship in Australian hospitals: defining the scope and future targets
Internal Medicine Journal · 2025
DOI: 10.1111/imj.16571 ↗Kurz gefasst
Fachartikel in der Zeitschrift Internal Medicine Journal, 2025. Verfasst von Karen F Urbancic und 5 weiteren Autor:innen. Beteiligte Einrichtung: National Centre for Infections in Cancer, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia. Hauptthemen laut MEDLINE: Antifungal Agents, Antimicrobial Stewardship, Invasive Fungal Infections, Hospitals. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 48 Literaturangaben. Gefördert von: National Health and Medical Research Council (NHMRC).
Abstract (Originalsprache)
Background
Antimicrobial stewardship (AMS) guidelines now recommend antifungal stewardship (AFS) interventions to improve the management of invasive fungal diseases (IFDs). AFS programmes have not been reported in Australia.
Aims
To determine the monitoring of antifungal use, AFS strategies and targets, and barriers to AFS implementation in Australian hospitals.
Methods
An electronic quantitative cross‐sectional survey was developed and distributed to public and private hospitals in Australia in February 2018. Descriptive statistics were used to summarise the findings.
Results
Eighty‐three Australian hospitals completed the survey with an overall response rate of 58% (83/143). Most hospitals monitored antifungal use (62/83, 75%). Frequently used AFS metrics included costs (48/60, 80%) and yearly point prevalence surveys (45/60, 75%). Core AFS strategies were commonly in place, including preauthorisation requirements (71/80, 89%) and expert antifungal post‐prescription review and feedback (PPRF) (63/80, 79%). Both these strategies were more strictly applied to high‐cost, intravenous agents. Formal education (44/79, 56%) and hospital‐endorsed guidelines (35/79, 44%) were modestly used. Fungal diagnostics and antifungal therapeutic drug monitoring (TDM) were utilised, largely off site. IFD surveillance was infrequently performed (9/77, 12%). Barriers to AFS identified included lack of staff time, prioritisation of AFS, and access to rapid diagnostics and TDM.
Conclusions
AFS strategies utilised in Australian hospitals have focused on high‐cost, intravenous agents. Although expert oversight of antifungals is evident, many sites omit potentially important targets for AFS, including fluconazole and oral posaconazole. Identifying these gaps and barriers to AFS will guide the development of an AFS model for hospitals.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- National Centre for Infections in Cancer, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
- National Centre for Antimicrobial Stewardship, Melbourne, Victoria, Australia.
- Department of Medicine, University of Melbourne, Melbourne, Victoria, Australia.
- Pharmacy Department, Austin Health, Melbourne, Victoria, Australia.
- Infectious Diseases Department, Austin Health, Melbourne, Victoria, Australia.
- Centre for Medicine Use and Safety, Monash University, Melbourne, Victoria, Australia.
ORCID-Profile: Karen F Urbancic, Michelle K Yong
Förderung
- National Health and Medical Research Council (NHMRC)
Zitieren
APA
Urbancic, K. F., Kong, D. C. M., Johnson, P. D. R., Yong, M. K., Slavin, M. A., & Thursky, K. (2025). Antifungal stewardship in Australian hospitals: defining the scope and future targets. Internal Medicine Journal. https://doi.org/10.1111/imj.16571
Vancouver
Urbancic KF, Kong DCM, Johnson PDR, Yong MK, Slavin MA, Thursky K. Antifungal stewardship in Australian hospitals: defining the scope and future targets. Internal Medicine Journal. 2025. doi:10.1111/imj.16571
BibTeX
@article{Urbancic2025,
author = {Urbancic, Karen F and Kong, David C M and Johnson, Paul D R and Yong, Michelle K and Slavin, Monica A and Thursky, Karin},
title = {Antifungal stewardship in Australian hospitals: defining the scope and future targets},
journal = {Internal Medicine Journal},
year = {2025},
doi = {10.1111/imj.16571}
}
EUVIMED